Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma

Bibliography

• Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41
   PubMed Web of Science ®Google Scholar
• Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 24:5576-83.2006
   PubMed Web of Science ®Google Scholar
• Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Nishioka C, Tasaka T, et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006;5:2522-30
   PubMed Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-83
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol 2012;2:13
   PubMedGoogle Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272-83
   PubMed Web of Science ®Google Scholar
• Wilmes LJ, Pallavicini MG, Fleming LM, et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007;25:319-27
   PubMed Web of Science ®Google Scholar
• Verzoni E, Grassi P, Testa I, et al. Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmgenomics Pers Med 2014;7:107-16
   PubMedGoogle Scholar
• Chen Y, Jiang J, Zhang J, et al. A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers. Int J Clin Pharmacol Ther 2011;49:679-87
   PubMed Web of Science ®Google Scholar
• Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010;65:563-70
   PubMed Web of Science ®Google Scholar
• Ueda T, Uemura H, Tomita Y, et al. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol 2013;43:616-28
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-84
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8
   PubMed Web of Science ®Google Scholar
• Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007;18:1117
   PubMed Web of Science ®Google Scholar
• Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17:3841-9
   PubMed Web of Science ®Google Scholar
• Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013;14:1233-42
   PubMed Web of Science ®Google Scholar
• Buti S, Porta C. Axitinib dose titration: what’s the limiting factor? Lancet Oncol 2013;14:1152-4
   PubMed Web of Science ®Google Scholar
• Rini BI, Melichar B, Fishman MN, et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 2015
   Google Scholar
• Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 2013;53:491-504
   PubMed Web of Science ®Google Scholar
• Tomita Y, Uemura H, Fujimoto H, et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 2011;47:2592-602
   PubMed Web of Science ®Google Scholar
• Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol 2014;66:874-80
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552-62
   PubMed Web of Science ®Google Scholar
• Escudier B, Michaelson MD, Motzer RJ, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014;110:2821-8
   PubMed Web of Science ®Google Scholar
• Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14:1287-94
   PubMed Web of Science ®Google Scholar
• M R: Inlyta (axitinib). Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM283657.pdf
   Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-9
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Maroto-Rey P, Trigo JM, et al. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clin Transl Oncol 2010;12:503-8
   PubMed Web of Science ®Google Scholar
• Rini B, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012;118:6152-61
   PubMed Web of Science ®Google Scholar
• Initial results from ASSURE (E2805). Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. Presented at the 2015 Genitourinary Cancers Symposium, Orlando, FL
   Google Scholar
• Alexandre I, Billemont B, Meric JB, et al. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol 2009;27:472-3
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Rixe O. Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 2009;4:297-305
   PubMed Web of Science ®Google Scholar
• Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010;46:439-48
   PubMed Web of Science ®Google Scholar
• Chen Y, Garrett M, Rini B, et al. Effect of renal impairment on the pharmacokinetics and safety of axitinib. Presented at the accepted at ASCPT Annual Meeting, New Orleans, LA., March 2015. 3-7
   Google Scholar
• Tortorici MA, Toh M, Rahavendran SV, et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs 2011;29:1370-80
   PubMed Web of Science ®Google Scholar
• Santoni M, Berardi R, Amantini C, et al. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer 2014;134:2772-7
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized, dose-ranging phase II trial. Presented at the ASCO Annual Meeting May 31 2014
   Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015
   Google Scholar
• Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66
   PubMed Web of Science ®Google Scholar
• Ko JS, Bukowski RM, Fincke JH. Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep 2009;11:87-93
   PubMed Web of Science ®Google Scholar
• Choueiri T, Figueroa D, Liu Y, et al. Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis. Presented at the Genitourinary Cancers Symposium, 2014
   Google Scholar
• Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma. Presented at the ASCO Annual Meeting, 31 May 2014
   Google Scholar
• Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 2010;101:963-8
   PubMed Web of Science ®Google Scholar
• Martin LP, Kozloff MF, Herbst RS, et al. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer 2012;107:1268-76
   PubMed Web of Science ®Google Scholar
• Kozloff MF, Martin LP, Krzakowski M, et al. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer 2012;107:1277-85
   PubMed Web of Science ®Google Scholar
• Spano JP, Moore MJ, Pithavala YK, et al. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2012;30:1531-9
   PubMed Web of Science ®Google Scholar
• Sharma S, Abhyankar V, Burgess RE, et al. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 2010;21:297-304
   PubMed Web of Science ®Google Scholar
• Available from: https://clinicaltrial.gov/ct2/results?term=axitinib+renal+cancer&pg=2
   Google Scholar